Acepodia Reveals US Regulatory Approval for Pioneering Anti-EGFR Allogeneic Cell Treatment Trial, Designated as ACE2016.

Regeneron Pharmaceuticals, Inc. revealed that the European Medicines Agency is reviewing their Marketing Authorization Application for the therapy, linvoseltamab.

4DMT Unveils Encouraging Early Results of the Phase 2 PRISM Study for the Eye Injection 4D-150, Indicating Good Safety and Efficacy in Treating Wet Age-Related Macular Degeneration.

Inmagene Biopharmaceuticals has announced its intention to acquire a solo, global license with royalties for IMG-007, a non-eliminating humanized antibody targeting OX40, and IMG-004, a systemically administered BTK inhibitor with non-covalent, reversible mechanisms.

European Medicines Agency Approves Review of Tisotumab Vedotin Filing for Relapsed or Spreading Cervical Cancer Therapy.

Ascendis Pharma unveils its second TransCon™ offering: YORVIPATH® hits markets in Germany and Austria, targeting chronic hypoparathyroidism in adults.

NeuroBo Pharmaceuticals has received approval from the FDA for a Phase 1 clinical study of DA-1726, a new drug aimed at managing obesity.

Halia Therapeutics has unveiled a $30 million Series C funding round to further develop their innovative range of treatments for inflammation.

Bio-Thera Solutions has launched an early-stage clinical study, specifically Phase 1B/2A, for its novel monoclonal antibody, BAT6026, aimed at OX40 for treating individuals experiencing moderate to intense eczema.

Recent findings on Genentech's drug Vabysmo indicate persistent efficacy in reducing retinal swelling and enhancing eyesight for those with Retinal Vein Occlusion.

RS Oncology Confirms Initial Participant Receives Dosage in Stage 2 Trial (MITOPE) Examining RSO-021 in Malignant Chest Tumor and Lung Metastases Therapy.

Sirius Therapeutics has initiated a first-stage clinical study for an advanced, extended-duration Factor XI siRNA anticoagulant, aimed at addressing thromboembolic conditions.